AstraZeneca PLC (AZN)

Market Cap	304.55B +43.5%
Revenue (ttm)	58.74B +8.6%
Net Income	10.23B +45.3%
EPS	6.54 +45.3%
Shares Out	1.55B
PE Ratio	29.78
Forward PE	19.08
Dividend	$3.20 (1.64%)
Ex-Dividend Date	Feb 20, 2026

Volume	1,578,965
Open	196.55
Previous Close	195.78
Day's Range	194.80 - 196.65
52-Week Range	129.15 - 212.71
Beta	0.28
Analysts	Strong Buy
Price Target	n/a
Earnings Date	Apr 29, 2026

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 12, 1993
• Employees: 95,100
• Stock Exchange: NYSE
• Ticker Symbol: AZN
• Website: https://www.astrazeneca.com

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.